BIOAFFINITY TECHNOLOGIES INC (BIAF)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-14
$7.93-0.25%
Close 2026-09-14 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-14
Research Workspace
Put BIAF beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Operating losses improve from negative $3.6M in Q1 2026: metric not reported.
View ThesisRevenue is contracting — down about 23% over the past year.
View GrowthManagement screens weak on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 4% on a typical day and fell roughly 97% in its worst 12-month stretch.
View RiskBIAF's growth depends on accelerating revenue through commercial initiatives. The recent nationwide distribution agreement for CyPath Lung supports this claim. Revenue grew 19% year over year, but the last quarter missed expectations. BIAF trades at 7.0× price-to-sales, above the peer median of 5.6×. This suggests the price reflects less growth than expected. A sharp drop of 42% may indicate a market repricing. The next-quarter miss probability is 63%. Peer multiples imply a price about 41% above where it trades. This read is provisional.
Trailing returns as of 2026-09-14. BIAF is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Continue this research
Compare BIAF with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| BIAF Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put BIAF next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Accelerate revenue growth through commercial initiatives
Nationwide agreement enhances revenue growth potential.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Maintain focus on cash flow management
Funding supports cash flow management and operational stability.
Advances: Maintain focus on cash flow management
Funding supports cash flow management objective.